Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability

被引:59
作者
Culpepper, Larry [1 ]
Muskin, Philip R. [2 ]
Stahl, Stephen M. [3 ,4 ,5 ]
机构
[1] Boston Univ, Sch Med, Dept Family Med, Boston Med Ctr, Boston, MA 02118 USA
[2] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA
[3] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[4] Neurosci Educ Inst, Carlsbad, CA USA
[5] Univ Cambridge, Dept Psychiat, Cambridge, England
关键词
Efficacy; Individualized Treatment; Major depression; Measurement based care; Multimodal antidepressants; Residual Symptoms; TREATMENT-RESISTANT-DEPRESSION; STAR-ASTERISK-D; SEROTONIN REUPTAKE INHIBITOR; MONOAMINE-OXIDASE INHIBITORS; RANDOMIZED CLINICAL-TRIAL; DOUBLE-BLIND; PRIMARY-CARE; ANTIDEPRESSANT TREATMENT; REFRACTORY DEPRESSION; ADJUNCTIVE THERAPY;
D O I
10.1016/j.amjmed.2015.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Major depressive disorder is a complex and frequent psychiatric condition that poses significant challenges to both the patients who experience it and the physicians who treat them. The goal of therapy is for patients to achieve remission, which requires identifying and measuring symptoms at the outset and throughout treatment to document both response and resistance to treatment. A number of validated instruments are available both for diagnosis of and response to treatment. Many factors affect a patient's ability to achieve remission, but although many patients do achieve remission, a significant number continue to have residual symptoms that cause functional impairment. METHODS: Review of the literature for treatment of major depression, including mechanisms of action, individualized treatment optimization, residual symptom reduction, and minimization of side effects. RESULTS: For sustained remission, all symptoms must be treated until they are undetectable. Patients who do not achieve remission after adequate treatment trials should be evaluated for adherence to treatment, as well as comorbid psychiatric and medical disorders. In these cases, consideration should be given to changing therapy by switching, combining, or augmenting initial therapy, as well as referring some patients to a psychiatrist for treatment with specialized modalities. Linking symptoms with malfunctioning brain circuits and neurotransmitters provides a targeted approach for achieving sustained remission. Neurobiology also provides a rational basis for combination therapy in patients with treatment-resistant depression, because it can aid selection of different drugs with different mechanisms of action or of multifunctional/ multimodal antidepressant drugs that target more than 1 molecular mechanism. DISCUSSION: Recent advances and better understanding of neurobiology provide a rational basis for individualizing treatment of patients with major depression. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:S1 / S15
页数:15
相关论文
共 107 条
[31]   Omega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder [J].
Gertsik, Lev ;
Poland, Russell E. ;
Bresee, Catherine ;
Rapaport, Mark Hyman .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2012, 32 (01) :61-64
[32]   Practical guide for prescribing MAOIs: debunking myths and removing barriers [J].
Grady, Meghan M. ;
Stahl, Stephen M. .
CNS SPECTRUMS, 2012, 17 (01) :2-10
[33]   The economic burden of depression in the United States: How did it change between 1990 and 2000? [J].
Greenberg, PE ;
Kessler, RC ;
Birnbaum, HG ;
Leong, SA ;
Lowe, SW ;
Berglund, PA ;
Corey-Lisle, PK .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (12) :1465-1475
[34]   The national depressive and manic-depressive association consensus statement on the undertreatment of depression [J].
Hirschfield, RMA ;
Keller, MB ;
Panico, S ;
Arons, BS ;
Barlow, D ;
Davidoff, F ;
Endicott, J ;
Froom, J ;
Goldstein, M ;
Horman, JM ;
Guthrie, D ;
Marek, RG ;
Maurer, TA ;
Meyer, R ;
Phillips, K ;
Ross, J ;
Schwenk, TL ;
Sharfstein, SS ;
Thase, ME ;
Wyatt, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :333-340
[35]   RETRACTED: Effect of Cognitive Therapy With Antidepressant Medications vs Antidepressants Alone on the Rate of Recovery in Major Depressive Disorder A Randomized Clinical Trial (Retracted Article) [J].
Hollon, Steven D. ;
DeRubeis, Robert J. ;
Fawcett, Jan ;
Amsterdam, Jay D. ;
Shelton, Richard C. ;
Zajecka, John ;
Young, Paula R. ;
Gallop, Robert .
JAMA PSYCHIATRY, 2014, 71 (10) :1157-1164
[36]   RESIDUAL SYMPTOMS AFTER REMISSION OF MAJOR DEPRESSIVE DISORDER WITH FLUOXETINE AND RISK OF RELAPSE [J].
Iovieno, Nadia ;
van Nieuwenhuizen, Adrienne ;
Clain, Alisabet ;
Baer, Lee ;
Nierenberg, Andrew A. .
DEPRESSION AND ANXIETY, 2011, 28 (02) :137-144
[37]  
JOFFE RT, 1993, ARCH GEN PSYCHIAT, V50, P387
[38]   Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? [J].
Judd, LL ;
Paulus, MJ ;
Schettler, PJ ;
Akiskal, HS ;
Endicott, J ;
Leon, AC ;
Maser, JD ;
Mueller, T ;
Solomon, DA ;
Keller, MB .
AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (09) :1501-1504
[39]   COLLABORATIVE MANAGEMENT TO ACHIEVE TREATMENT GUIDELINES - IMPACT ON DEPRESSION IN PRIMARY-CARE [J].
KATON, W ;
VONKORFF, M ;
LIN, E ;
WALKER, E ;
SIMON, GE ;
BUSH, T ;
ROBINSON, P ;
RUSSO, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (13) :1026-1031
[40]  
Kennedy Sidney H, 2007, Ann Clin Psychiatry, V19, P279, DOI 10.1080/10401230701675222